International Journal of Social Sciences and Management Review

EVENT STUDY ON DRUG APPROVALS – IMPACT OF ORPHAN DRUG APPROVALS ON THE SHAREHOLDER VALUE OF PHARMACEUTICAL COMPANIES

Authors: Jan-luca Rolf, B.A., Gianfranco Marotta, DBA, M.sc. & Alexander Zureck, Prof. Dr.

ABSTRACT

The pharmaceutical industry is controversially discussed. Nevertheless, there is a con-sensus that the need for new medicines is undeniable. In particular, the treatment of rare diseases with orphan drugs is characterized by a high unmet medical need. Regulatory incentive schemes seek to stimulate orphan drug research and development (R&D). This is also reflected in the increasing approvals during the last two decades. Orphan drugs have gained relevance and become a more attractive business for pharmaceutical compa-nies (Blonda et al., 2021, p. 2)

Keywords: #Event-Study; Pharmaceutical Industry; # Rare Diseases; #Shareholder Value

BIBLIOGRAPHY

• Bachelier, L. (1900). Théorie de la spéculation. Annales Scientifiques de l’École Normale Supérieure, 17, 21–86. https://doi.org/10.24033/asens.476
• Baker, H. K., Filbeck, G., & Kiymaz, H. (2020). Equity Markets, Valuation, and Analy-sis. Wiley.
• Ball, R. (2009). The Global Financial Crisis and the Efficient Market Hypothesis: What Have We Learned? Journal of Applied Corporate Finance, 21(4), 8–16. https://doi.org/10.1111/j.1745-6622.2009.00246.x
• Ballwieser, W., & Hachmeister, D. (2013). Unternehmensbewertung: Prozess, Methoden und Probleme. Schäffer-Poeschel .
• Batram, M., Witte, J., Greiner, W., & Gensorowsky, D. (2022). AMNOG Report 2022.
• Baumgarth, C., Eisend, M., & Evanschitzky, H. (2009). Empirische Mastertechniken (C. Baumgarth, M. Eisend, & H. Evanschitzky, Eds.). Gabler Verlag. https://doi.org/10.1007/978-3-8349-8278-0
• Benninga, S. (2014). Financial Modeling (Fourth edition). The MIT Press.
• Blonda, A., Denier, Y., Huys, I., & Simoens, S. (2021). How to Value Orphan Drugs? A Review of European Value Assessment Frameworks. Frontiers in Pharmacolo-gy, 12. https://doi.org/10.3389/fphar.2021.631527
• Bloomberg. (n.d.). Bloomberg. Retrieved March 9, 2023, from https://www.bloomberg.com/subscriptions/yTAOdl37xPb73LM?utm_medium=cpc_search&utm_campaign =BR _ACQ_BRAND_BRANDGENERALX_EVG_XXXX_XXX_Y0469_EN_EN_X_BLOM_GO_SE_XXX_XXXXXXX XXX&gclid=Cj0KCQiApKagBhC1ARIsAFc7Mc4HkIVFUIm0uedHb3-9iu3uC3LLGJKnSpoXkBs-cHXmNjYW1YUQkz0aAvpWEALw_wcB&gclsrc=aw.ds
• Bowman, R. G. (1983). UNDERSTANDING AND CONDUCTING EVENT STUD-IES. Journal of Business Finance & Accounting, 10(4), 561–584. https://doi.org/10.1111/j.1468-5957.1983.tb00453.x
• Brasil, S., Pascoal, C., Francisco, R., dos Reis Ferreira, V., A. Videira, P., & Valadão, G. (2019). Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter? Genes, 10(12), 978. https://doi.org/10.3390/genes10120978
• Brown, S. J., & Warner, J. B. (1980). MEASURING SECURITY PRICE PERFO-MANCE. Journal of Financial Economics, 205–258.
• Brown, S. J., & Warner, J. B. (1985). Using daily stock returns. Journal of Financial Economics, 14(1), 3–31. https://doi.org/10.1016/0304-405X(85)90042-X
• Burton, A. L. (2021). OLS (Linear) Regression. In The Encyclopedia of Research Meth-ods in Criminology and Criminal Justice (pp. 509–514). Wiley. https://doi.org/10.1002/9781119111931.ch104
• Chen, J. M. (2021). The Capital Asset Pricing Model. Encyclopedia, 1(3), 915–933. https://doi.org/10.3390/encyclopedia1030070
• Cheng, P. L., & Deets, M. K. (1971). PORTFOLIO RETURNS AND THE RANDOM WALK THEORY. The Journal of Finance, 26(1), 11–30. https://doi.org/10.1111/j.1540-6261.1971.tb00585.x
• Chuang-Stein, C., & Kirby, S. (2017). Quantitative Decisions in Drug Development. Springer International Publishing. https://doi.org/10.1007/978-3-319-46076-5
• Dolley, J. C. (1933). Open Market Buying as a Stimulant for the Bond Market. Journal of Political Economy.
• Cleff, T. (2008). Deskriptive Statistik und moderne Datenanalyse: eine computergestützte Einführung mit Excel, SPSS und STATA. Gabler.
• Das Europäische Arzneimittelregulierungssystem: Ein einheitlicher Ansatz für die Zulassung von Arzneimitteln in der Europäischen Union. (2016).
• Gupta, S. (2011). Drug Discovery and Clinical Research. (2011). Jaypee Brothers Medi-cal Publishers (P) Ltd. https://doi.org/10.5005/jp/books/11216
• Mücke, M., Conrad, R. (2021). Seltene Erkrankungen in der Inneren Medizin. Elsevier. https://doi.org/10.1016/C2016-0-00077-3
• EMA. (n.d.-a). European Medicines Agency. Retrieved November 10, 2022, from https://www.ema.europa.eu/en
• EMA. (n.d.-b). European public assessment reports: background and context. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/medicines/what-we-publish-when/european-public-assessment-reports-background-context
• EMA. (n.d.-c). Fees payable to the European Medicines Agency. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/human-regulatory/overview/fees-payable-european-medicines-agency
• EMA. (n.d.-d). How the committees work. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/committees/how-committees-work
• EMA. (n.d.-e). Marketing authorisation. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation
• EMA. (n.d.-f). Marketing authorization holder. Retrieved November 10, 2022, from https://www.ema.europa.eu/en/glossary/marketing-authorisation-holder
• EMA. (n.d.-g). Orphan designation: Overview. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview
• EMA. (n.d.-h). Orphan incentives. Retrieved March 8, 2023, from https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives
• EMA. (2019). Procedures for marketing authorisation (Vol. 2A). European Commission – Health and Food Safety Directorate General.
• Fama, E. F. (1970). Efficient Capital Markets: A Review of Theory and Empirical Work. The Journal of Finance, 25(2), 383. https://doi.org/10.2307/2325486
• Fama, E. F. (1991). Efficient Capital Markets: II. The Journal of Finance, 46(5), 1575–1617. https://doi.org/10.1111/j.1540-6261.1991.tb04636.x
• Fama, E. F., & French, K. R. (2004). The Capital Asset Pricing Model: Theory and Evi-dence. Journal of Economic Perspectives, 18(3), 25–46. https://doi.org/10.1257/0895330042162430
• FASB. (1995). Statement of Financial Accounting Standards No.123 (pp. 1–134).
• Franco, P. (2013). Orphan drugs: the regulatory environment. Drug Discovery Today, 18(3–4), 163–172. https://doi.org/10.1016/j.drudis.2012.08.009
• From laboratory to patient: the journey of a medicine assessed by EMA. (2019).
• Gehrke, M. (2019). Ereignisstudie. In Angewandte empirische Methoden in Finance & Accounting (pp. 269–286). De Gruyter. https://doi.org/10.1515/9783110586251-008
• Gerke, W. (2013). Gerke Börsen Lexikon. Gabler Verlag.
• Gerpott, T. J. (2009). Ereignisstudie. In Empirische Mastertechniken (pp. 203–234). Gabler Verlag. https://doi.org/10.1007/978-3-8349-8278-0_7
• Giannuzzi, V., Conte, R., Landi, A., Ottomano, S. A., Bonifazi, D., Baiardi, P., Bonifazi, F., & Ceci, A. (2017). Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet Journal of Rare Diseases, 12(1), 64. https://doi.org/10.1186/s13023-017-0617-1
• Gindiyeh, M. (2013). Anwendung wahrscheinlichkeitstheoretischer Methoden in der linguistischen Informationsverarbeitung. Logos.
• Goerke, B. (2009). Event-Studies. In Methodik der empirischen Forschung (pp. 467–484). Gabler Verlag. https://doi.org/10.1007/978-3-322-96406-9_30
• Gorry, P., & Useche, D. (2017). Orphan Drug Designations as Valuable Intangible As-sets for IPO Investors in Pharma-Biotech Companies.
• Graf von der Schulenburg, J.-M., & Frank, M. (2015). Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. The European Journal of Health Economics, 16(2), 113–118. https://doi.org/10.1007/s10198-014-0639-8
• Günther, M., & Velten, K. (2015). Mathematische Modellbildung und Simulation: Eine Einführung für Wissenschaftler, Ingenieure und Ökonomen. Wiley.
• Gurgul, H., Majdosz, P., & Mestel, R. (2007). On applications of regression of regres-sion models in event studies on financial markets.
• Hall, A. K., & Carlson, M. R. (2014a). The current status of orphan drug development in Europe and the US. Intractable & Rare Diseases Research, 3(1), 1–7. https://doi.org/10.5582/irdr.3.1
• Hall, A. K., & Carlson, M. R. (2014b). The current status of orphan drug development in Europe and the US. Intractable & Rare Diseases Research, 3(1), 1–7. https://doi.org/10.5582/irdr.3.1
• Hauser, S. E. (2003). Informationsverarbeitung am Neuen Markt : eine empirische Analyse der Determinanten von Kursreaktionen auf Ad-hoc-Meldungen.
• Honek, J. (2017). Preclinical research in drug development . Medical Writing , 20(4).
• EURORDIS. (n.d.). Our Vision & Mission. Retrieved March 8, 2023, from https://www.eurordis.org/de/wer-wir-sind/our-vision-mission/
• Hübel, A., Schmelcher, T., & Storz, U. (2012). Biopatent Law: Patent Strategies and Patent Management. Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-24846-7
• Leach, L. F., & Henson, R. K. (2007). Multiple Linear Regression Viewpoints: The use and impact of adjusted R2 effects in published regression research (Vol. 33). University of Alabama.
• Lemke, T., Krahnhof, P., & Zureck, A. (2022). Ereignisstudie und Text Mining: Untersuchung der Wirkung von Ad-hoc-Meldungen auf den Kapitalmarkt im Kontext der Behavioral Finance (pp. 117–139). https://doi.org/10.1007/978-3-658-35831-0_5
• Lenhard, R. (2009). Erfolgsfaktoren von Mergers & Acquisitions in der europäischen Telekommunikationsindustrie. Gabler. https://doi.org/10.1007/978-3-8349-8191-2
• MacKinlay, C. (1997). Event Studies in Economics and Finance. Journal of Economic Literature, Vol. 35, 13–39.
• Malkiel, B. G. (2003). The Efficient Market Hypothesis and Its Critics. Journal of Eco-nomic Perspectives, 17(1), 59–82. https://doi.org/10.1257/089533003321164958
• Mayr, L. M., & Fuerst, P. (2008). The Future of High-Throughput Screening. SLAS Dis-covery, 13(6), 443–448. https://doi.org/10.1177/1087057108319644
• McWilliams, A., & Siegel, D. (1997). Event Studies in Management Research: Theoreti-cal and Empirical Issues. The Academy of Management Journal, 40, 626–657.
• Meekings, K. N., Williams, C. S. M., & Arrowsmith, J. E. (2012). Orphan drug devel-opment: an economically viable strategy for biopharma R&D. Drug Discovery Today, 17(13–14), 660–664. https://doi.org/10.1016/j.drudis.2012.02.005
• Michaeli, D. T., Yagmur, H. B., Achmadeev, T., & Michaeli, T. (2022). Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and In-vestors. Therapeutic Innovation & Regulatory Science, 56(2), 313–322. https://doi.org/10.1007/s43441-021-00364-y
• Mikulic, M. (2022, September). Global prescription orphan drug sales from 2012 to 2026.
• Miller, K. L. (2017). Do investors value the FDA orphan drug designation? Orphanet Journal of Rare Diseases, 12(1), 114. https://doi.org/10.1186/s13023-017-0665-6
• MSCI World Factsheet. (2022).
• Müller, A., & Reuse, S. (2022). Impact of Brexit news on the stock prices of european insurance companies: an event study approach based on indexation and sub-indexation. Zeitschrift Für Die Gesamte Versicherungswissenschaft, 111(3), 379–407. https://doi.org/10.1007/s12297-022-00534-3
• Murakami, M., & Narukawa, M. (2016). Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan. Drug Discovery Today, 21(4), 544–549. https://doi.org/10.1016/j.drudis.2016.02.016
• Naseer, M., & bin Tariq, Y. (2015). The Efficient Market Hypothesis: A Critical Review of the Literature. The IUP Journal of Financial Risk Management, 12, 1–17.
• Ng, R. (2015). Drugs: From Discovery to Approval . Wiley.
• Orphanet. (n.d.). Orphan drugs in Japan. Retrieved March 8, 2023, from https://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=DE&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_JAP
• Orphanet. (n.d.). Orphan drugs in Australia. Retrieved March 8, 2023, from https://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_AUS
• Peterson, J., & Shackleton, M. (2012). The Institutions of the European Union . OUP Oxford.
• Picavet, E., Morel, T., Cassiman, D., & Simoens, S. (2014). Shining a light in the black box of orphan drug pricing. Orphanet Journal of Rare Diseases, 9(1), 62. https://doi.org/10.1186/1750-1172-9-62
• Prinz, A. (2008). Ethik und Ökonomik in der pharmazeutischen Industrie. In Bittere Arznei (pp. 13–43). Brill | Fink. https://doi.org/10.30965/9783846745304_003
• Procedural advice for orphan medicinal product designation: Guidance for sponsors. (2022).
• Raynor, D. K., & Bryant, D. (2013). European Public Assessment Report (EPAR) sum-maries for the public: are they fit for purpose? A user-testing study. BMJ Open, 3(9), e003185. https://doi.org/10.1136/bmjopen-2013-003185
• Read, C. (2013). The Efficient Market Hypothesists. Palgrave Macmillan UK. https://doi.org/10.1057/9781137292216
• Réda, C., Kaufmann, E., & Delahaye-Duriez, A. (2020). Machine learning applications in drug development. Computational and Structural Biotechnology Journal, 18, 241–252. https://doi.org/10.1016/j.csbj.2019.12.006
• Refinitiv. (n.d.). Refinitiv. Retrieved March 9, 2023, from https://www.refinitiv.com/en#
• Reinhardt, D. (2017). Inverkehrbringen von Arzneimitteln und Medizinprodukten. Springer Fachmedien Wiesbaden. https://doi.org/10.1007/978-3-658-16367-9
• Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., & Hughes, D. A. (2015). Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 18(6), 906–914. https://doi.org/10.1016/j.jval.2015.05.008
• Röder, K. (1999). Kurswirkungen von Meldungen deutscher Aktiengesellschaften (Vol. 98).
• Rosenberg-Yunger, Z. R. S., Daar, A. S., Thorsteinsdóttir, H., & Martin, D. K. (2011). Priority setting for orphan drugs: An international comparison. Health Policy, 100(1), 25–34. https://doi.org/10.1016/j.healthpol.2010.09.008
• Sander, B. (2015). Neue Aktienstrategien für Privatanleger. FinanzBuch Verlag.
• Sarkar, S. K., & de Jong, P. J. (2006). Market response to FDA announcements. The Quarterly Review of Economics and Finance, 46(4), 586–597. https://doi.org/10.1016/j.qref.2005.01.003
• Sathyanarayana, S. S., & Gargesha, S. (2017). The Impact of Policy Announcements on Stock Market Volatility: Evidence from Currency Demonetisation in India. Journal of Business and Management, 19(1), 47–63.
• Schäfer, T. (2016). Methodenlehre und Statistik. Springer Fachmedien Wiesbaden. https://doi.org/10.1007/978-3-658-11936-2
• Scheufele, B., & Haas, A. (2008). Medien und Aktien: Theoretische und empirische Modellierung der Rolle der Berichterstattung für das Börsengeschehen. VS Verlag für Sozialwissenschaften.
• Schmidt, D. (2022a). Kapitalmarktreaktionen aufAd-hoc-Mitteilungen: Eine empirische Analyse am deutschen Aktienmarkt im Kontext wirtschaftlicher Krisen. Masarykova Univerzita.
• Schmidt, D. (2022b). Kapitalmarktreaktionen auf Ad-hoc-Mitteilungen: Eine empirische Analyse am deutschen Aktienmarkt im Kontext wirtschaftlicher Krisen. Masarykova Univerzita.
• Schöffski, O., Fricke, F.-U., & Guminski, W. (Eds.). (2008). Pharmabetriebslehre. Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-79551-3
• Scholz, N. (2015). Arzneimittel in der Europäischen Union: Der Rechtsrahmen für Humanarzneimittel.
• Schwarzer, M. (2003). Kursreaktionen auf Unternehmensmeldungen bei unterschiedlichen Unternehmenssituationen: Eine empirische Untersuchung am deutschen Kapitalmarkt. Universität Hildesheim.
• Sharma, A., & Lacey, N. (2004). Linking Product Development Outcomes to Market Valuation of the Firm: The Case of the U.S. Pharmaceutical Industry*. Journal of Product Innovation Management, 21(5), 297–308. https://doi.org/10.1111/j.0737-6782.2004.00084.x
• Simoens, S. (2011). Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet Journal of Rare Diseases, 6(1), 42. https://doi.org/10.1186/1750-1172-6-42
• Sireau, N. (2017). Rare Diseases (N. Sireau, Ed.). Routledge. https://doi.org/10.4324/9781351278409
• Song. (2012). Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable & Rare Diseases Research. https://doi.org/10.5582/irdr.2012.v1.1.3
• Sorescu, A., Warren, N. L., & Ertekin, L. (2017). Event study methodology in the mar-keting literature: an overview. Journal of the Academy of Marketing Science, 45(2), 186–207. https://doi.org/10.1007/s11747-017-0516-y
• S&P Global 1200 Factsheet. (2022).
• Stedman, T. L. (2005). Stedman’s medical dictionary for the health professions and nurs-ing. Lippincott Williams & Wilkins.
• Steinmetz, K. L., & Spack, E. G. (2009). The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurology, 9(Suppl 1), S2. https://doi.org/10.1186/1471-2377-9-S1-S2
• Stoller, J. K. (2018). The Challenge of Rare Diseases. Chest, 153(6), 1309–1314. https://doi.org/10.1016/j.chest.2017.12.018
• Studenmund, A. H. (2014). Using Econometrics: A practical Guide (Sixth Edition). Pearson.
• Sturm, A. (2007). Auswirkungen von Medikamentengenehmigungen auf die Bewertung von Biotech- und Pharmaunternehmen: Eine Ereignisstudie. Universität Regensburg.
• Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, 12(7), 3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002
• Suryanto, S. (2015). Analysis of abnormal return before and after the announcement of investment grade indonesia. International Journal of Business Management Review, 3, 11–23.
• Szylar, C. (2013). Handbook of Market Risk (C. Szylar, Ed.). Wiley. https://doi.org/10.1002/9781118572979
• Tamimi, N. A. M., & Ellis, P. (2009). Drug Development: From Concept to Marketing! Nephron Clinical Practice, 113(3), c125–c131. https://doi.org/10.1159/000232592
• Taylor, C., Jan, S., & Thompson, K. (2018). Funding therapies for rare diseases: an ethi-cal dilemma with a potential solution. Australian Health Review, 42(1), 117. https://doi.org/10.1071/AH16194
• vfa. (n.d.). vfa. Die forschenden Pharma-Unternehmen. Retrieved November 10, 2022, from https://www.vfa.de/
• vfa. (2018). So entsteht ein neues Medikament. https://www.vfa.de/de/arzneimittel-forschung/so-funktioniert-pharmaforschung/so-entsteht-ein-medikament.html
• vfa. (2023). Medikamente gegen seltene Erkrankungen. https://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/orphan-drugs-medikamente-gegen-seltene-erkrankungen.html
• Wallstreet Online. (n.d.). Wall Street Online. Retrieved November 10, 2022, from https://www.wallstreet-online.de
• Warfsmann, J. (2013). Das Capital Asset Pricing Model in Deutschland. Deutscher Uni-versitätsverlag.
• Wastfeld, M., Fadeel, B., & Henter, J.-I. (2006). A journey of hope: lessons learned from studies on rare diseases and orphan drugs. Journal of Internal Medicine, 260(1), 1–10. https://doi.org/10.1111/j.1365-2796.2006.01666.x
• Webb, S. M., Kristensen, J., Nordenström, A., Vitali, D., Amodru, V., Wiehe, L. K., & Bolz-Johnson, M. (2022). Patient journey experiences may contribute to improve healthcare for patients with rare endocrine diseases. Endocrine Connections, 11(12). https://doi.org/10.1530/EC-22-0385
• Weber, S., & Grüters-Kieslich, A. (2017). Seltene Erkrankungen. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz, 60(5), 477–478. https://doi.org/10.1007/s00103-017-2542-9
• Wetterauer, B., & Schuster, R. (2008). Seltene Krankheiten. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz, 51(5), 519–528. https://doi.org/10.1007/s00103-008-0524-7
• Whaley, R. E. (2007). Derivatives: Markets, Valuation, and Risk Managament. Wiley.
• Wilson, C. (2013). Orphan drugs and orphan drug legislation. In Orphan Drugs (pp. 9–53). Elsevier. https://doi.org/10.1533/9781908818393.9
• Wood, J., Sames, L., Moore, A., & Ekins, S. (2013). Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discovery Today, 18(21–22), 1043–1051. https://doi.org/10.1016/j.drudis.2013.08.006
• Wright, C. F., FitzPatrick, D. R., & Firth, H. v. (2018). Paediatric genomics: diagnosing rare disease in children. Nature Reviews Genetics, 19(5), 253–268. https://doi.org/10.1038/nrg.2017.116
• Yen, G., & Lee, C. (2008). Efficient Market Hypothesis (EMH): Past, Present and Fu-ture. Review of Pacific Basin Financial Markets and Policies, 11(02), 305–329. https://doi.org/10.1142/S0219091508001362
• Yücel, S. (2015). Prognontizierbarkeit deutscher Aktien auf Grundlage von aggregierten Informationssignalen am Beispiel des Scoring-Konzeptes. disserta Verlag.
• Zureck, A. (2016). Eine kapitalmarktorientierte Analyse der Ökonomisierung des Fußballs im Kontext der Behavioral Finance.